Overall, the 5-year survival rate for adults is 23.4%.1 Complete remission (CR) was achieved in 35%C40% of adult patients aged 60 years or younger and 5%C15% among patients older than 60 years of age.2 Mortality in patients with AML can result from treatment-related causes, relapse or primary refractoriness. of patients with AML. We will search for any eligible articles from selected electronic databases. We will follow the Preferred Reporting Items for Systematic reviews and Meta-Analysis for study selection and reporting. We will use The Cochrane Handbook for Systematic Reviews of Interventions and Meta-Analysis as guidance to select eligible studies. All data will be extracted using a standardised data extraction form. Ethics and dissemination There was no patient involved in this study, therefore no ethical consideration is needed. The findings of this study will be disseminated in a peer-reviewed journal and any relevant conference presentation. PROSPERO registration number CRD42019123286. strong class=”kwd-title” Keywords: acute myeloid leukaemia, gemtuzumab ozogamicin, safety, efficacy, systematic review Strengths and limitations of this study We will do a wide search on all data from various databases, for example, Cochrane, PubMed, EMBASE and clinical trials. This study will discuss in detail about the methods for conducting a systematic review. The study will only include randomised controlled trials. The study will summarise the evidence and plan the meta-analysis for data that we can pool together. Introduction Acute myeloid leukaemia (AML) is a term used to represent a heterogeneous group of diseases resulting from a malignant change in the haematopoietic stem cells. In the USA, the overall incidence rate and the death rate are 3.6 and 2.8 per 100?000 people per year, respectively. The incidence increases with age, with 40% of cases occurring in adults aged below 60 years and more than 50% in patients aged 60 years and above. Overall, the 5-year survival rate for adults is 23.4%.1 Complete remission (CR) was achieved in 35%C40% of adult patients aged 60 Bimosiamose years or younger and 5%C15% among patients older than 60 years of age.2 Mortality in patients with AML can result from treatment-related causes, relapse or primary refractoriness. The mortality rate is approximately 50% in patients aged 60 years or younger and about 80% in patients aged 60 years and above.3 4 Prognostic factors can be subdivided into two categories: patient-associated factors and disease-related factors. Patient-associated factors, such as advanced age, performance status and coexisting conditions, commonly predict treatment-related risks, whereas disease-related factors, such as tumour burden (white blood cell count), secondary AML (AML resulting from either antecedent haematological disorder or prior chemotherapy treatment) and genetic changes, are used to predict resistance to current standard therapy.5 6 Of these prognostic factors, molecular genetic Bimosiamose lesions are additionally found to be highly predictive markers of survival.5 7 8 These markers are used in risk classification. The National Comprehensive Cancer Network defines three risk subgroups based on their cytogenetic and molecular abnormalities, namely Bimosiamose favourable or better-risk, intermediate-risk and poor-risk.4 9 The treatment for AML consists of induction, consolidation Rabbit Polyclonal to Galectin 3 and maintenance phases.2 10 Standard induction therapy for patients aged less than 60 years most often consists of cytarabine (cytosine arabinoside (Ara-C)) given by continuous infusion for 7?days with an anthracycline (such as daunorubicin and idarubicin) given daily for 3?days.9 The standard of care for consolidation consists of three to four courses of high-dose intravenous Ara-C given every 12?hours on day 1, 3 and 5.11 Chemotherapy is often not recommended for Bimosiamose patients in poor health because of its toxicity. Besides antileukaemic drugs, patients would also receive supportive care such as treatment of infections (prophylactic administration of antifungal and antibacterial agent)12 and transfusions to cover anaemia or thrombocytopenia.13 14 Bimosiamose Gemtuzumab ozogamicin (GO) is one of the new class of monoclonal antibodies used in the treatment of AML. GO is a recombinant humanised anti-CD33 monoclonal antibody conjugated to the antitumour antibiotic, calicheamicin, which permits the drug to be targeted selectively to the CD33-positive.